Vaccines ‘Made in Africa’: Considerations on building local vaccine production capacity

Africa is a large market for vaccines but has very little local production capacity. The continent accounts for 25% of global demand for vaccines (not just coronavirus vaccines) but manufactures only 1% locally. During the pandemic this has created major bottlenecks in the supply of the population and caused major health issues and serious social harm. In order to remedy the situation and create better conditions for future health crises, the African Union (AU) aims to have 60% of the vaccines used in Africa manufactured on the continent by 2040. But which African countries are suitable vaccine manufacturing locations?

Vaccines ‘Made in Africa’: Considerations on building local vaccine production capacity(PDF, 369 KB, accessible)